FDA class I recall for Insulet Omnipod 5 raises patient safety concerns

The U.S. FDA has classified Insulet's Omnipod 5 recall as a Class I action, the agency’s highest risk category, indicating that a defect could cause serious health problems or death for users. The recall pertains to certain affected lots and underscores the potential severity of the issue for patients relying on the insulin-delivery system.

A manufacturing defect has been linked to small cracks in the internal tubing of the insulin pods, with reports noting defective tubing and missing alarms. The situation has led to a substantial number of injury reports following the recall, highlighting the scope of safety concerns for thousands of diabetes patients who use Omnipod 5.

Insulet is cooperating with regulators to address the defect and implement safeguards to prevent further risk, while patients are advised to monitor for device issues and follow recall guidance issued by the company and authorities.